A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19
NCT ID: NCT04558021
Last Updated: 2020-10-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
200 participants
INTERVENTIONAL
2020-10-08
2021-02-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to evaluate the safety and efficacy profile of niclosamide from the test product (Niclosamide 200 mg/10 mL Suspension) in patients treated for the novel coronavirus infectious disease (COVID-19) in a placebo controlled phase III trial. Both treatment groups will receive an established treatment regimen against COVID-19 together with either niclosamide or placebo.
The efficacy and safety of the molecule is well-known and the properties of novel formulation is well-established. The promising in vitro results of niclosamide as an antiviral compound is well documented and make it an ideal candidate as a therapy against SARS-CoV 2 infection. A good safety profile is expected with solid antiviral activity.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
NCT04858425
Niclosamide for Mild to Moderate COVID-19
NCT04399356
Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19
NCT04423861
Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers
NCT04576312
Niclosamide in COVID-19
NCT04542434
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The medications for the established treatment regimen will be supplied by Ministry of Health to the study sites. The other study medications, Investigational product and placebo, together with relative documentation, will be supplied to clinical sites by the sponsor. Niclosamide 200 mg/10 mL Suspension and placebo will be supplied together with certificates of analysis by the company responsible for manufacturing of the test product(s).The packaging and labelling of niclosamide and placebo will be done according to the GMP and GCP requirements.
All subjects will receive either 200 mg/10 mL niclosamide suspension or 10 mL placebo three times a day for 5 days, together with an established COVID-19 treatment regimen according to the official guidance for COVID-19 Adult Treatment Algorithm of Republic of Turkey Ministry of Health. Dosings will be administered in accordance with the treatment randomization table throughout the treatment duration.
On each drug administration, the identity of the subject will be confirmed by checking the Identity Card. Administration of the study medication will be performed by the investigator(s) and nurse(s) and supervised by a second medical professional to ensure the correctness of drug administration. Also, a monitor may attend during this procedure. The administration of the study medication is to be followed by a mouth check, to be documented in the CRF and certified by the Investigator.
The statistical analysis will be done according to the provisions of ICH Topic E9, Statistical Principles for Clinical Trials (CPMP/ICH/363/96), September 1998.
Statistical analysis will be performed as a valid case analysis including all subjects in which no major protocol deviations occurred and all primary target variables are available for measurement.
If a subject is to be excluded from evaluation, this decision has to be justified in the Final Study Report.
Continuous variables will be expressed as means ± standard deviations (SD) for the normally distributed data or median with interquartile (IQR) for the skewed data. Correspondingly, two-sample independent t-test and Mann-Whitney U test will be used to detect the difference between groups. Categorical variables will be described as number (%) and compared by χ² test or Fisher's exact test as appropriate. Kaplan-Meier method will be used to estimate the cumulative probability of the endpoint. Cox proportional hazards regression model will be conducted to determine the potential risk factors associated with the endpoint. Statistical significance will be defined as p\<α=0.0054 for interim analysis, p\<α=0.0492 for final analysis using O'Brien-Fleming alpha adjustment. All analyses will be done with R project.
The expected percentage of treatment success is 75% in the experimental group and 50% in the control group. The sample size calculation yields that 170 subjects are needed (85 for each group) to achieve 90% power at α=0.05. Considering potential dropouts, the sample size is estimated as 200 subjects (100 subjects for each group). For interim analysis, 100 subjects (50 subjects for each group) will be evaluated.
Before being enrolled to the clinical study, the subject(s) must consent to participate in the study by signing the informed consent form in response to a complete written and verbal explanation of the nature, scope and possible consequences of the clinical study explained in an understandable way for him/her by the physician.
Each subject will give in writing her/his authorization that the study data may be given for review to the responsible Local and National Authorities.
The subject information and informed consent form will be provided in duplicate \[one signed version (original 1) will be left at the investigator; the other signed version (original 2) will be forwarded to the subject\].
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention Arm-I
Niclosamide 200 mg/10 mL Suspension will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health
Niclosamide suspension
200mg/10ml
Intervention Arm-II
10 mL placebo will be administered to patients 3 times a day for 5 days along with the treatment regimen selected according to the official guidance for COVID-19 Adult Treatment Algorithm established by Republic of Turkey Ministry of Health
Placebo
10ml placebo(absent of niclosamide)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Niclosamide suspension
200mg/10ml
Placebo
10ml placebo(absent of niclosamide)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Adult hospitalized patients (aged ≥18) confirmed or suspected for COVID-19 according to the official General Information, Epidemiology and Diagnosis Guidance for COVID-19 (SARS-CoV-2 Infection) published by Republic of Turkey Ministry of Health showing at least one of the symptoms below:
1. fever, cough, difficulty in breathing, sore throat, headache, muscle or body aches, new loss of taste or smell, diarreha without explanation of any cause than COVID-19 and history of herself/himself or her/his close contact presenting in the high-risk area of the disease within 14 days prior to the onset of symptoms or
2. at least one of the symptoms of fever, cough, difficulty in breathing, sore throat, headache, muscle or body aches, new loss of taste or smell, diarrhea without explanation of any cause than COVID-19 and close contact with confirmed COVID-19 case within 14 days prior to symptoms or
3. fever and at least one of the signs and symptoms of the severe acute respiratory infection (cough and difficulty in breathing) and need for hospitalization due to severe acute respiratory infection (SARI) explanation failure of the clinical features other than COVID-19 SARI: The need for hospitalization in a patient with acute respiratory infection due to fever, cough and dyspnea, tachypnea, hypoxemia, hypotension, wide radiological findings and consciousness developing in the last 14 days.
or
4. at least two of the signs and symptoms of fever, cough, difficulty in breathing, sore throat, headache, muscle or body aches, new loss of taste or smell, diarrhoea without explanation of any cause than COVID-19 or
3. Patients detected with SARS-COV-2 by molecular methods who meet the criteria for possible case of SARS-COV-2
14. Who is not eligible to swallow oral medications,
15. Who use vitamin C as supplementary medication during the study,
16. Who are included in another trial.
Exclusion Criteria
2. Who is diagnosed as "severe or critical case" (e.g. pneumonia or severe pneumonia),
3. Whose National Early Warning Score 2 (NEWS2) score is indicated as "urgent" or "emergency",
4. Any history of bone marrow transplant, solid-organ transplant, immune compromising conditions, immunomodulatory therapy, haematologic malignancy,
5. Who have Multiple Sclerosis,
6. Who have electrolyte imbalance, chronic haemodialysis or glomerular filtration rate \< 30 30 mL/min/1.73m2,
7. Who have history of serious cardiovascular diseases,
8. Who are diagnosed with another ongoing viral infection other than SARS CoV-2,
9. Who have macrophage activation syndrome,
10. Who have a need for coagulopathy treatment,
11. Who have severe liver disease,
12. Who is pregnant or nursing,
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imuneks Farma ilac San. Tic. A.S.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aydin Erenmemisoglu, Prof.Dr.
Role: STUDY_DIRECTOR
ALPAN Farma Ltd.Sti.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Akdeniz Üniversitesi Tıp Fakültesi Hastanesi
Antalya, , Turkey (Türkiye)
Antalya Eğitim ve Araştırma Hastanesi
Antalya, , Turkey (Türkiye)
Gaziantep Üniversitesi Tıp Fakültesi Hastanesi
Gaziantep, , Turkey (Türkiye)
Gaziosmanpaşa Taksim Eğitim ve Araştırma Hastanesi
Istanbul, , Turkey (Türkiye)
Dokuz Eylül Üniversitesi Hastanesi
Izmir, , Turkey (Türkiye)
İzmir SBÜ Tepecik Eğitim ve Araştırma Hastanesi
Izmir, , Turkey (Türkiye)
SBÜ Dr. Suat Seren Göğüs Hastalıkları ve Cerrahisi Eğitim ve Araştırma Hastanesi
Izmir, , Turkey (Türkiye)
İzmir Katip Çelebi Üniversitesi Atatürk Eğitim ve Araştırma Hastanesi
Izmir, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Wu CJ, Jan JT, Chen CM, Hsieh HP, Hwang DR, Liu HW, Liu CY, Huang HW, Chen SC, Hong CF, Lin RK, Chao YS, Hsu JT. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6. doi: 10.1128/AAC.48.7.2693-2696.2004.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NOV2020/01930
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.